In the last trading session, 2.36 million Processa Pharmaceuticals Inc (NASDAQ:PCSA) shares changed hands as the company’s beta touched 1.37. With the company’s per share price at $0.32 changed hands at $0.02 or 8.02% during last session, the market valuation stood at $3.86M. PCSA’s last price was a discount, traded about -868.75% off its 52-week high of $3.10. The share price had its 52-week low at $0.15, which suggests the last value was 53.12% up since then.
Analysts gave the Processa Pharmaceuticals Inc (PCSA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended PCSA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Processa Pharmaceuticals Inc’s EPS for the current quarter is expected to be 0.
Processa Pharmaceuticals Inc (NASDAQ:PCSA) trade information
Instantly PCSA was in green as seen at the end of in last trading. With action 8.96%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -63.26%, with the 5-day performance at 8.96% in the green. However, in the 30-day time frame, Processa Pharmaceuticals Inc (NASDAQ:PCSA) is 18.50% up.
The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need an upside of 96.44% from its current market value. According to analyst projections, PCSA’s forecast low is 9 with 9 as the target high. To hit the forecast high, the stock’s price needs a -2712.5% plunge from its current level, while the stock would need to soar -2712.5% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 22.65%. The 2025 estimates are for Processa Pharmaceuticals Inc earnings to increase by 77.00%, but the outlook for the next 5-year period is at 42.13% per year.
PCSA Dividends
Processa Pharmaceuticals Inc is expected to release its next quarterly earnings report in July.
Among Mutual Funds, the top two as of Mar 31, 2025 were Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . With 29.24 shares estimated at $9494.0 under it, the former controlled 0.25% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held about 0.21% of the shares, roughly 24.43 shares worth around $7933.0.
